Drug Profile
NN 9513
Alternative Names: HypoPen 1513; NN9513; NNC9204 1513Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihypercalcaemics; Antihypoglycaemics; Pancreatic hormones
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypoglycaemia
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Hypoglycaemia(In volunteers) in Germany (SC, Injection)
- 24 May 2018 Novo Nordisk completes a phase I trial in Hypoglycaemia (In volunteers) in Germany (SC) (NCT03444467)
- 05 Feb 2018 Phase-I clinical trials in Hypoglycaemia (In volunteers) in Germany (SC) (NCT03444467) (Novo Nordisk pipeline, May 2018)